Information Provided By:
Fly News Breaks for June 14, 2019
GBT
Jun 14, 2019 | 10:28 EDT
H.C. Wainwright analyst Debjit Chattopadhyay believes the data this morning from Global Blood Therapeutics "continues to de-risk the story." He believes the package for voxelotor supports accelerated approval and that Global Blood is now a "logical bolt on acquisition candidate for one of the large hematology-centric franchises." He reiterates a Buy rating on the shares with a $150 price target. Chattopadhyay says that while the Street remains fixated on a lack of statistically significant benefit in vaso-occlusive crises from a study "that was not powered for such," he defers to the October 2018 FDA workshop directed at preventing end-organ damage by lowering hemolysis as a "marked evolution in the thought process at the agency."
News For GBT From the Last 2 Days
There are no results for your query GBT